Bioqual, Inc. Reports Earnings Results for the Second Quarter Ended November 30, 2019
January 21, 2020 at 04:05 pm
Share
Bioqual, Inc. announced earnings results for the second quarter ended November 30, 2019. For the second quarter, the company announced sales was USD 11.222 million compared to USD 8.361 million a year ago. Net income was USD 891,841 compared to USD 574,313 a year ago. Basic earnings per share was USD 1 compared to USD 0.64 a year ago. For the half year, sales was USD 21.290 million compared to USD 18.014 million a year ago. Net income was USD 2.216 million compared to USD 1.201 million a year ago. Basic earnings per share was USD 2.48 compared to USD 1.35 a year ago.
Bioqual, Inc. is engaged in performing contract research services, which is focused on in vivo models of human diseases, including COVID-19, acquired immune deficiency syndrome (AIDS), influenza, Mpox, respiratory syncytial virus (RSV) infection, Flavivirus infections, including zika and dengue, malaria, hepatitis, and cancer. It is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. The Company also performs in vitro contract research services. The in vitro services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation and other cell-based assays. It also provides research services in herpes simplex in rodents, filariasis in rhesus macaques, chikungunya in rodents and macaques and dengue in rodents and macaques.
BIOQUAL, INC. 
